Large-scale testing (Phase 3)Study completedNCT00489970
What this trial is testing
Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9
Who this might be right for
Acellular PertussisTetanusDiphtheria
GlaxoSmithKline 1,954